Currently, effective vaccines are lacking for many diseases, in particular chronic and intracellular infections where protection is thought to depend on T cell-mediated immunity. Tuberculosis is one of the best examples of this category, and central to the success of Mycobacterium tuberculosis (Mtb) as a pathogen is its ability to subvert host immune responses and establish latent infection 1 . The BCG vaccine is currently the only tuberculosis vaccine approved for human use. However, in the last five years there has been substantial progress in the tuberculosis vaccine field, with several vaccines either in clinical trials or on their way through preclinical development 2 . These vaccines are all designed as prophylactic vaccines for preinfection administration and are in most cases based on antigens recognized by the immune system during the early stage of infection 3 . Evidence from mouse models suggests that although these new vaccines represent improvements over BCG, none of them results in sterilizing immunity 4, 5 . Similarly, BCG does not prevent the establishment of latent persistent tuberculosis infection, as clearly demonstrated by the immense numbers of latently infected individuals worldwide and the reactivation of clinical disease as a consequence of HIV infection and immune suppression 6, 7 . Among the candidates in the first generation of new tuberculosis vaccines developed to replace or supplement BCG is a fusion of the two early secreted antigens, Ag85B and ESAT-6, that have an extensive track record both as individual vaccine antigens 4, [8] [9] [10] [11] and as the H1 fusion protein 4, [11] [12] [13] [14] . Although H1 as a booster may improve upon the efficacy of BCG, recent epidemiological modeling has highlighted the importance of reducing transmission by protecting infected people from progressing to active tuberculosis by vaccination either before or after exposure 15 .
Mtb differs from many other pathogens in its ability to survive in an intracellular habitat for years. It achieves this long-term intracellular persistence by controlling phagosomal maturation, preventing phagosomal fusion with the lysosome and reducing acidification of the phagosome 16 . To restict Mtb growth, infected monocytes attract additional monocytes, macrophages and T cells, and an organized aggregate (granuloma) is formed. Mimicking conditions thought to reflect the environment inside the granuloma in vitro and evaluating the transcriptional response has been the subject of intensive research in recent years, and strategies have included hypoxia 17, 18 and nutrient starvation 19 . Our hypothesis is that it is possible to selectively target the bacteria in the persistent stage of infection by combining antigens with preventive vaccine activity, such as Ag85B and ESAT-6, with targets preferentially expressed as the bacteria adapt to long-term persistence in the immune host. Here we show that as Mtb adapts to persistence, it downregulates many genes characteristic of the early stage of infection. Among the genes that are expressed at unchanged levels in the early and late stages of infection is Rv2660c. Expression of this gene has previously been reported to be 80-to 300-fold increased in nutrient-starved cultures, making it the most strongly upregulated of all the nutrient starvation-induced genes identified 19 , and Rv2660c is also part of the transcriptional response to hypoxia 18, 20 and activated macrophages 21 . In this study we report on the design, construction and evaluation before and after Mtb exposure of a new multistage vaccine, H56, that combines Ag85B, ESAT-6 and Rv2660c.
All tuberculosis vaccines currently in clinical trials are designed as prophylactic vaccines based on early expressed antigens. We have developed a multistage vaccination strategy in which the early antigens Ag85B and 6-kDa early secretory antigenic target (ESAT-6) are combined with the latency-associated protein Rv2660c (H56 vaccine). In CB6F1 mice we show that Rv2660c is stably expressed in late stages of infection despite an overall reduced transcription. The H56 vaccine promotes a T cell response against all protein components that is characterized by a high proportion of polyfunctional CD4 + T cells. In three different pre-exposure mouse models, H56 confers protective immunity characterized by a more efficient containment of late-stage infection than the Ag85B-ESAT6 vaccine (H1) and BCG. In two mouse models of latent tuberculosis, we show that H56 vaccination after exposure is able to control reactivation and significantly lower the bacterial load compared to adjuvant control mice. a r t i c l e s 1 9 0 VOLUME 17 | NUMBER 2 | FEBRUARY 2011 nature medicine
RESULTS

Gene expression in various stages of Mtb infection
We compared the gene expression profile of 28 selected Mtb genes in the early (weeks 2 and 3 after infection) and late (weeks 20 and 30 after infection) stages of infection in the lungs of CB6F1 mice infected by the aerosol route. We reverse-transcribed and amplified total RNA isolated from individual mice before we quantified the PCR products in individual real-time PCR reactions 22, 23 . Use of multiple internal controls allowed accurate quantification of transcripts in each sample across multiple specimens. The 28 genes represented markedly different classes of genes with roles in metabolism, stress responses or host-pathogen interactions.
In two independent studies, we found a reduction in the general expression profile in the later stages of infection, where 19 of the 28 genes were expressed at a level at least 50% lower than in the early stages. The expression of the classical heat shock protein HspX (hspX, Rv2031c) was lower but still highly expressed at the late stage of infection ( Table 1) . Six genes (fadE5, Rv0244c; sigE, Rv1221; Rv2030c; Rv2660c; sigB, Rv2710 and ppsD, Rv2934) were expressed at the same level in the early and late stages of infection ( Table 1) . Apart from ppsD (Rv2934), these genes are all involved in stress responses.
Initial evaluation of H56 and its protein components To construct the H56 vaccine, we purified the recombinant H56 fusion protein (Ag85B-ESAT6-Rv2660c) from Escherichia coli (Fig. 1a) and formulated it with a cationic adjuvant (CAF01) 14 . Groups of CB6F1 mice were vaccinated three times with doses from 0.01 to 10 µg. Six weeks later, we challenged the mice with Mtb (Erdman) by the aerosol route and enumerated bacteria in the lungs 6 weeks later (Fig. 1b) . Vaccinated mice were protected at all H56 doses, but the best protection occurred with a 5-µg dose, resulting in a 1.25 ± 0.08 log 10 reduction of lung colony-forming units (CFU) compared to the adjuvant control group (P < 0.001), but not significantly different from BCG (1.01 ± 0.12 log 10 ).
After determining the optimal dose, we compared immune responses and protection by H56 and its individual components. In all groups, we found vaccine-specific responses, but the immunogenicity of the single proteins varied considerably, with Ag85B being the most immunogenic and Rv2660c being the least (Fig. 1c) . H56 vaccination promoted a stronger response against all three components than vaccines based on the individual antigens. Six weeks after vaccination, we challenged the mice and determined the bacterial loads in their lungs 6 weeks later (Fig. 1d) . Both Ag85B and ESAT-6 vaccination induced moderate protection, but only Ag85B was statistically different from the control a r t i c l e s nature medicine VOLUME 17 | NUMBER 2 | FEBRUARY 2011 1 9 1 group (P < 0.05). Rv2660c was of low immunogenicity ( Fig. 1c) and did not protect the mice (Fig. 1d) . In contrast, H56 vaccination efficiently controlled bacterial growth (P < 0.001) to the same degree as the BCG control vaccine (Fig. 1d) . We then conducted a 24-week evaluation of H56 and BCG in mice challenged with Mtb (H37Rv). At all time points investigated, the H56-immunized group had significantly lower bacterial counts in the lungs than the control group (P < 0.01), but at the two late time points (12 and 24 weeks after challenge) H56 also performed significantly better than the BCG vaccine (P < 0.05) (Fig. 1e) .
Comparative evaluation of H56 and H1
We decided to compare H56 vaccination to vaccination with the H1 fusion on which it is based. H56-vaccinated mice responded with higher levels of interferon-γ (IFN-γ) to both Ag85B and ESAT-6 than H1-vaccinated mice and also had a specific IFN-γ response against Rv2660c that was not present in the H1-vaccinated mice (Fig. 2a) . All mice, including a BCG-vaccinated control group, were challenged with Mtb, and the course of the infection was followed for 24 weeks. At the time of challenge, we found strong responses to the vaccine components Ag85B and ESAT-6 in both H1-and H56-vaccinated mice, whereas we found no significant immune responses against these antigens in BCG-vaccinated mice (Fig. 2b) . As the infection developed, the strength of the immune responses specific for all three vaccine antigens increased.
In the initial phase of infection, the immune response to Rv2660c was at the same level as in nonvaccinated mice but from week 6 and onward we could detect an increasing response in H56-vaccinated mice (Fig. 2b) . By flow cytometry we observed a large population of cytokine-positive, antigen-specific CD4 + T cells that could be isolated from perfused lungs 6, 12 and 24 weeks after infection. The CD4 + T cells were directed to all three components of H56 but had the a b a r t i c l e s 1 9 2 VOLUME 17 | NUMBER 2 | FEBRUARY 2011 nature medicine strongest response to Ag85B and ESAT-6. We found no detectable vaccine-specific CD8 + T cells in the lungs (Supplementary Fig. 1 ). H56-vaccinated mice preferentially accumulated Ag85B-specific, triplepositive (interleukin-12 (IL-2) + tumor necrosis factor-α (TNF-α) + IFN-γ + ), double-positive (IL-2 + TNF-α + and IFN-γ + TNF-α + ) and TNF-α single-positive CD4 + T cells in the lung at weeks 6, 12 and 24 after infection (Fig. 2c) . We also found polyfunctional CD4 + T cell subsets in H1-vaccinated mice but the frequencies were lower at all time points (Fig. 2c) . In the adjuvant and BCG vaccinated group, the majority of the infection-induced Ag85B-and ESAT-6-specific CD4 + T cells were found in the IFN-γ + single-positive population. These differences were particularly evident at the late time point 24 weeks after infection (Fig. 2c) .
The bacterial load in infected mice showed the same overall profile as we had seen before when comparing the H56 vaccine with BCG (Fig. 1e) . In the early stage of infection (<week 4) the three vaccines gave a similar level of protection, and the bacterial numbers were reduced by approximately 1.5 log 10 in all vaccination groups at week 4 after infection relative to the saline control group (Fig. 2d) . However, from week 12 onward, H56 was superior to H1 (P < 0.05) and at week 24 also to BCG (P < 0.05). The sustained H56 vaccine activity at a time point where both H1 and BCG had waning activity indicate an additional advantage of H56 and the Rv2660c antigen in late stages of infection.
Boosting BCG with H56 and H1 Three months after mice were vaccinated with BCG, we investigated the ability of H56 to boost the BCG vaccine. Peripheral blood mononuclear cells (PBMCs) showed minimal responses 1 week after the final vaccination in the BCG group, whereas both H1-and H56-boosted groups had Ag85B-and ESAT-6-specific responses, and H56-boosted mice also had a Rv2660c-specific response (Supplementary Fig. 2) .
Six weeks after vaccination, the mice were challenged, and the bacterial counts in the lungs were enumerated 6 and 24 weeks after challenge. Six weeks after challenge, all mice in the BCG-vaccinated groups had significantly fewer bacilli in the lungs than the control mice (P < 0.001) (Fig. 3a) . Both H1-and H56-boosted mice had slightly lower bacterial counts than the BCG-vaccinated mice (Fig. 3a) . However, 24 weeks after infection, H56 boosting was better and the bacterial loads in these mice (1.87 ± 0.04 log 10 CFU reduction) were significantly lower than both the BCG-vaccinated (1.05 log 10 CFU reduction, P < 0.01) and the H1-boosted mice (1.46 ± 0.11 log 10 CFU reduction, P < 0.05, Fig. 3b ).
In agreement with the observations above (Fig. 2c) , the CD4 + T cells recruited to the lungs in H56-boosted mice were predominantly vaccine-specific polyfunctional T cells. This confirms the ability of the H56 vaccine to promote high-quality (polyfunctional) T cell responses even in BCG-vaccinated mice (data not shown).
Vaccination with H56 after exposure To establish a model for vaccination after exposure, we infected mice by aerosol exposure followed by antibiotic treatment (Fig. 4a) . After treatment, the bacterial load was low but we obtained robust In experiments 4-6, mice received two vaccinations, and the bacterial load was measured 23 weeks after infection. The CFU values are shown as scattered plots with the median indicated (n = 12-16 per group in each experiment). We used the Mann-Whitney U test for comparison among groups. *P < 0.05; **P < 0.01; ***P < 0.001. Data are means ± s.e.m. reactivation from week 22 after infection onward. In six independent experiments, we used H56 formulated in CAF01 adjuvant to vaccinate mice after exposure. We measured vaccine-induced immune responses in PBMCs 35 weeks after infection (Fig. 4b) . In agreement with the hierarchy of responses found after preventive vaccination with H56 (Fig. 1c) , vaccination after exposure with H56 gave a T cell response that was focused toward Ag85B and ESAT-6, with modest recognition of Rv2660c. Adjuvant control mice were characterized by a low but detectable response against ESAT-6 (Fig 4b) . Thirtyfive weeks after infection, we characterized vaccine-specific CD4 + T cells (there was no specific recognition in the CD8 + subset) by flow cytometry. H56 vaccination resulted in a four-to six-fold increase in antigen-specific CD4 + T cells compared to control mice (from 0.2-0.3% to 1-1.5% of accumulated cytokine-positive cells) (Fig. 4c) .
The H56 vaccine-specific T cells were polyfunctional CD4 + T cells expressing IFN-γ, IL-2 and TNF-α (data are shown for Ag85B, but ESAT-6 gave a similar pattern) (Fig. 4c and data not shown) . This distribution was in clear contrast to the control mice, in whom the infection-induced T cell response towards Ag85B and ESAT-6 was at a much lower frequency and almost exclusively found among IFN-γ + TNF-α + double-positive CD4 + T cells (Fig. 4c) .
We evaluated the protective efficacy of H56 vaccination after exposure in mice killed 23-43 weeks after infection by assessing the bacterial load in lung homogenates from individual mice. In six independent experiments performed in two different laboratories, we found that H56 consistently provided a significant degree of protection against reactivation in mice (Fig. 4d) . This was demonstrated in both the CB6F1 mouse model and in a similar model established in C57BL/6 mice (Fig. 4d) . We found some variation in the bacterial burden, but there was statistically significant (P < 0.05) protection in all experiments (0.8-1.6 log 10 reduction of CFU). Histological examination of lung samples showed normal lung tissue with a few scattered, small, lymphocyte-rich granulomas in both vaccinated and adjuvant control groups (data not shown). In some experiments the tendency was fewer and smaller granulomas in the vaccinated group, but these differences were not significant.
DISCUSSION
We have presented a vaccine strategy designed to improve the longterm containment of Mtb and prevent reactivation by vaccination either before or after exposure. We hypothesize that it is possible to target the bacteria in the late stage of infection and prevent reactivation by combining early protective antigens (here Ag85B and ESAT-6) with proteins that are preferentially expressed as the bacteria adapt to long-term persistence in a host with a fully developed adaptive immune system. We selected Rv2660c because it is associated with the major transcriptional response as the bacteria adapt to nutrient starvation 19 and because we found here that it is stably expressed in late stages of infection characterized by reduced overall transcription level of most of the genes analyzed. We have shown that vaccination both before and after exposure with the triple fusion H56 results in an immune response that encompasses all three protein components and protects mice against tuberculosis. Protection was evident in the various phases of the infection up to at least 24 weeks after infection. In the late persistent stage of infection, the effect of adding Rv2660c was particularly pronounced, and we found the H56 vaccine to be almost ten times more efficient at reducing the bacterial number than the H1 vaccine. In agreement with the activity of H56 against the late stages of infection, we observed a detectable recognition of Rv2660c from week 6 of infection. Notably, we detected this response only in mice primed with the Rv2660c-containing vaccine. Rv2660c is of low immunogenicity in CB6F1 mice, and our data suggest that whereas responses to this antigen remain below the detection level during primary Mtb infection, prior vaccination with H56 primes a Rv2660c-specific response that is recalled during infection. BCG expression of Rv2660c has been shown in vitro 24 , but, owing to its attenuation, BCG probably does not persist long enough to promote a response to latency antigens 25 . Nevertheless, late-stage vaccine activity was also evident in BCG boost experiments; H1 and H56 gave similar levels of protection at week 6, but H56 boosted a response that was significantly more efficient in the late stages of infection. We also found that H56 had a very substantial activity when administered after exposure in modified Cornell models 26 , and it promoted immune responses that contained the infection with CFU counts ten to 50 times below that found in adjuvant control mice.
We have shown that the late persistent stage of infection is characterized by reduced transcription of prominent antigens that are expressed during the early stage of infection and that genes involved in protein translation or metabolism are downregulated, indicating a lower metabolic activity and replication. Six genes (fadE5, sigE, Rv2030c, Rv2660c, sigB and ppsD) are expressed at the same level in the early and late stages of infection, and, with the exception of ppsD, these genes are all involved in stress responses that characterize the long-term adaptation to a host with a fully developed adaptive immune response. The σ factors are key bacterial transcription regulators implicated in the adaptation of Mtb to environmental changes, intracellular stress and bacterial virulence 27, 28 . Rv2030c is part of the DosR regulon induced by hypoxic conditions 29 . FadE5 is involved in the lipid degradation that is the primary source of energy and building blocks during latency. The function of Rv2660c is presently unknown, but the protein is highly upregulated under nutrient starvation 19 and in the enduring response to hypoxia 18 , both conditions thought to reflect the intracellular conditions in the persistent stage of infection. In vivo expression profiles from Mtb residing in human granulomas suggest that Rv2660c is expressed during the latent persistent stage of human disease (http://www.tbdb.org/cgi-bin/data/rtpcr.pl?sd=GC1 1h&ex=Dan2&s=submit), and recent data have shown that latently infected individuals have a higher and more frequent Rv2660c-specific T cell response than individuals with active tuberculosis disease 30 .
Rv2660c does not confer a protective immune response on its own in our studies, something we observed both at early (Fig. 1d) and late (data not shown) time points. Although we do not fully understand this discrepancy, we believe it relates to immunogenicity and T cell help. Rv2660c has a low immunogenicity in CB6F1 mice, but the immune responses are amplified five-to tenfold by incorporating it into H56, and that may bring responses up to protective levels. This is in agreement with previous observations where improved immunogenicity was obtained by incorporating ESAT-6 or TB10.4 (a small ESAT-6 family protein) into fusions constructs containing the highly immunogenic Ag85B molecule 4, 31, 32 . It is possible that Rv2660c only reaches its true potential in concert with immunogenic antigens, because the immune response toward these early antigens provides sufficient IL-2 to expand clones of late-reactive T cells.
Recent reports from a number of disease models have shown that T cells with multiple effector functions, such as the concomitant production of IFN-γ, TNF-α and IL-2, are functionally superior to their single-positive counterparts [33] [34] [35] [36] [37] [38] . We used multiparameter flow here to analyze the quality of the T cell response at the site of infection in the mice immunized with the various vaccines. These analyses showed that the vaccine promoted CD4 + T cells that were almost exclusively polyfunctional, and after post-exposure vaccination these cells replaced the IFN-γ + TNF-α + double-positive effector cells characteristic of the infection-driven response. The background for the induction and maintenance of polyfunctional T cells possibly relates to the use of the CAF01 adjuvant system. CAF01 is known to efficiently target antigens to activated dendritic cells over prolonged periods of time 14 , resulting in strong and long-lived polyfunctional CD4 + memory T cells 39 . On the basis of the unique activity found after vaccination with H56 before and after exposure, it is our hope that reactivation and, consequently, outbreak of active tuberculosis could be delayed and transmission reduced, and we have therefore recently initiated clinical development of H56.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
